Anti-IL-12 p40 antibody (ab106270)
Key features and details
- Rabbit polyclonal to IL-12 p40
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-IL-12 p40 antibody
See all IL-12 p40 primary antibodies -
Description
Rabbit polyclonal to IL-12 p40 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Recombinant full length protein corresponding to Human IL-12 p40 aa 23-328.
Database link: BC067499 -
Positive control
- Human fetal liver lysate; Human fetal colon tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Lyophilized:Reconstitute with 200ul distilled sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary. -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituent: 1% BSA -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab106270 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/2000. Detects a band of approximately 46 kDa (predicted molecular weight: 37 kDa).
|
|
IHC-P |
1/100 - 1/500.
|
Notes |
---|
WB
1/1000 - 1/2000. Detects a band of approximately 46 kDa (predicted molecular weight: 37 kDa). |
IHC-P
1/100 - 1/500. |
Target
-
Function
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.
Associates with IL23A to form the IL-23 interleukin, an heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to an heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis. -
Involvement in disease
Defects in IL12B are a cause of mendelian susceptibility to mycobacterial disease (MSMD) [MIM:209950]; also known as familial disseminated atypical mycobacterial infection. This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity, whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood, whereas others develop, later in life, disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance.
Genetic variations in IL12B are a cause of susceptibility to psoriasis type 11 (PSORS11) [MIM:612599]. Psoriasis is a common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. -
Sequence similarities
Belongs to the type I cytokine receptor family. Type 3 subfamily.
Contains 1 fibronectin type-III domain.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain. -
Post-translational
modificationsKnown to be C-mannosylated in the recombinant protein; it is not yet known for sure if the wild-type protein is also modified. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 3593 Human
- Entrez Gene: 16160 Mouse
- Entrez Gene: 64546 Rat
- Omim: 161561 Human
- SwissProt: P29460 Human
- SwissProt: P43432 Mouse
- SwissProt: Q9R278 Rat
- Unigene: 674 Human
see all -
Alternative names
- CLMF antibody
- CLMF p40 antibody
- CLMF2 antibody
see all
Images
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab106270 has been referenced in 4 publications.
- Xu J et al. IL-23, but not IL-12, plays a critical role in inflammation-mediated bone disorders. Theranostics 10:3925-3938 (2020). PubMed: 32226529
- Yao W et al. Intratumoral injection of dendritic cells overexpressing interleukin-12 inhibits melanoma growth. Oncol Rep 42:370-376 (2019). PubMed: 31115558
- Umezawa N et al. Interleukin-23 as a therapeutic target for inflammatory myopathy. Sci Rep 8:5498 (2018). PubMed: 29615652
- Helbling M et al. Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. Oncotarget 5:4671-82 (2014). PubMed: 25015728